Hints and tips:
...The Dutch-Swiss ingredients and bioscience group just lowered its profit projection for the year....
...Dutch ingredients and bioscience group DSM and Swiss fragrance and flavour specialist Firmenich have announced a €41bn deal to create a “global powerhouse” in the specialist products needed for a booming...
...The charity focuses on “translational research” — driving bioscience as quickly as possible into benefits for patients....
...Horizon Discovery half-year results One UK company that may see only upside from an international move is small gene editing bioscience group Horizon Discovery....
...Mr Wijers started by spinning off Organon to Schering Plough in 2007....
...company’s decision to close its flagship centre operating since the 1950s, it has agreed to maintain 650 employees on the site, and has negotiated to lease space to three life science companies, Mylan, York Bioscience...
...In his most controversial move, Mr Wijers sold the Organon pharmaceuticals company, the Netherlands’ largest, to Schering-Plough in order to tighten AkzoNobel’s focus on paints and chemicals....
...Dutch pharmaceuticals and chemicals group DSM, the world’s largest producer of vitamins, announced a $1.1bn takeover of Martek Biosciences, a US maker of baby food ingredients, sending shares in DSM up 3.9...
...Martek Biosciences soared 35.6 per cent to $31.67 after the baby food ingredients maker agreed to be bought by DSM, a Dutch group....
...Nokia shares dipped 1.4 per cent to €9.36.Dutch biotech group Fornix BioSciences said it would sell its allergy unit for a lower-than-expected €19.6m to Copenhagen’s ALK-Abello, with the sale price hit by...
...Quarterly sales rose 63 per cent to $4.58bn, boosted by sales of products acquired in the company’s takeover of Organon BioSciences last year, and from a favourable foreign exchange rate....
...Schering-Plough said profit declined 48 per cent to $291m because of costs associated with buying Organon Biosciences for $16bn in November – but the figure was ahead of most analysts’ estimates....
...In March, Schering Plough, the US pharmaceuticals group, beat private equity firms in the auction for Organon Biosciences, an Akzo Nobel-owned pharmaceuticals unit....
...“Akzo Nobel believes that ICI would represent a highly attractive addition to its focused coatings and chemicals business following the announced sale of Organon BioSciences N.V. earlier this year....
...Akzo is also looking to sell its pharmaceutical unit Organon to Schering-Plough for $14.4bn. Akzo stock has gained more than 7.7 per cent since it announced the sale of its drug business....
...Schering has made efforts to reduce its dependence on cholesterol drugs, particularly with its $14bn acquisition of Organon BioSciences....
...Akzo Nobel said it had rejected private equity advances for Organon Biosciences, its drugs division, and reaffirmed plans to float a minority of the unit....
...Akzo Nobel, the Dutch chemicals conglomerate, said on Thursday an IPO of its Organon Biosciences pharmaceutical division was “imminent” as it reported record full-year results and said it was “well-placed...
...The sale of Organon Biosciences marks a fresh step in consolidation of the mid-size pharmaceutical sector and is likely to help drive up prices for coming deals including the planned sale of the generics...
...The sale this year by Akzo Nobel of its Organon Biosciences medicines division has left only Bayer of Germany as a significant European conglomerate that still embraces both chemicals and pharmaceuticals...
...Schering reported net income of $713m or 45 cents per common share compared with $287m, or 19 cents per share, a year earlier, including a big boost related to the acquisition of Akzo Nobel NV’s Organon...
...“A chief executive in the biosciences industry told me that every time he drives past the university, he says: ‘There’s my research lab’,” says Drummond Bone, vice-chancellor....
...Schering-Plough had been stalking the Organon unit for as long as two years, and Organon’s experimental drug to treat precisely that condition has had a recent shift in its fortunes....
International Edition